ロード中...

Sorafenib for the treatment of hepatocellular carcinoma

The multikinase inhibitor sorafenib, which inhibits targets related to tumor cell proliferation and angiogenesis, was the first systemic agent to demonstrate a significant improvement in the overall survival for patients with advanced hepatocellular carcinoma (HCC) in two large randomized controlled...

詳細記述

保存先:
書誌詳細
出版年:Hepat Oncol
主要な著者: Wörns, Marcus Alexander, Galle, Peter Robert
フォーマット: Artigo
言語:Inglês
出版事項: Future Medicine Ltd 2014
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6095169/
https://ncbi.nlm.nih.gov/pubmed/30190954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep.13.20
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!